LONDON, November 11, 2015 /PRNewswire/ --
-- ENDOCUFF VISION(R) may lead to an overall saving in colorectal cancer treatment
costs of over EUR5 million Norgine B.V. today announced new data showing that ENDOCUFF VISION(R), a colonoscope device, when used with a 2L polyethylene glycol + ascorbate components bowel preparation, may improve the adenoma detection rate (ADR), which may reduce the development of colorectal cancer, avoid treatment costs and reduce mortality. These data were presented at the ISPOR Annual Congress 2015.(1)
(Logo: http://photos.prnewswire.com/prnh/20130829/633895-a )
The model, that uses a cohort of 10,000 German patients eligible for screening, demonstrates that use of the device with a 2L polyethylene glycol + ascorbate components bowel preparation can help to improve the ADR compared to the use of bowel preparation alone. This increased ADR can help avoid progression to colorectal cancer in more patients. Furthermore, the model shows that despite an increase in the overall cost due to repeat colonoscopies, use of the device leads to a saving in colorectal cancer treatment costs of EUR283 per person screened over 10 years, resulting in an overall saving of over EUR5 million.
ENDOCUFF VISION(R) is a device attached at the end of the colonoscope that opens up the field of view by retracting folds during withdrawal.
Peter Martin, Chief Operating Officer at Norgine said: "We know that the detection and removal of adenomas during colonoscopy substantially reduces both the development of and death from colorectal cancer. Today's data are an important milestone that further underscores the vital role that ENDOCUFF VISION(R) can play for patients and health systems by significantly improving detection of tumors."
The prevalence of cancer of the large bowel in Germany is estimated at 48,677 men and women every year.(2)
ENDOCUFF VISION(R) is available in Austria, Denmark, Germany, Ireland, Norway, Spain, Sweden, Switzerland and UK.
(1) The addition of a novel colonoscope device improves adenoma detection in a German screening population which may result in cost savings due to fewer cases of colorectal cancer. Abstract PMD61. ISPOR Annual Congress 2015.
(2) Prevalence of large bowel cancer in Germany. http://eco.iarc.fr/eucan/Country.aspx?ISOCountryCd=276 . [Accessed 4 November 2015] See full release on www.norgine.com [http://www.norgine.com ]
Isabelle Jouin : +44 (0)1895 453643
Charlotte Andrews: +44 (0)1895 453669
Follow us @norgine